Latest News

  • INSIGHTS

    24 Jan 2026

    AbbVie’s RemeGen Bet Highlights a Shift in Cancer Strategy

  • RESEARCH

    19 Jan 2026

    Pfizer Moves Deeper Into ADCs With Pivotal Lung Cancer Trials

  • PARTNERSHIPS

    14 Jan 2026

    In Precision Oncology, Smart Alliances Are Beating Big Buys

  • REGULATORY

    8 Jan 2026

    Orphan Drug Incentives Shape Next Wave of Cancer Deals

A Small Deal With a Big Message for US Cancer Drugmakers

A Small Deal With a Big Message for US Cancer Drugmakers

INVESTMENT

14 Nov 2025

Day One’s Mersana buy shows how US drugmakers are moving earlier to lock up promising antibody-drug conjugates

Faster or Failed? ADC Developers Rethink How Drugs Get Built

PARTNERSHIPS

23 Oct 2025

Faster or Failed? ADC Developers Rethink How Drugs Get Built

Invenra and Xcellon Biologics link discovery and manufacturing early to speed next-generation ADCs toward the clinic

Cancer’s guided missiles grow up

INNOVATION

2 Oct 2025

Cancer’s guided missiles grow up

AbbVie, Pfizer and Merck advance antibody drug conjugates through late-stage trials and regulatory filings in a shift towards precision on...

A Regulatory Signal That Precision Cancer Care Is Maturing

INNOVATION

16 Sep 2025

A Regulatory Signal That Precision Cancer Care Is Maturing

FDA backing for a next-generation ADC underscores growing confidence in targeted cancer drugs and signals faster momentum across oncology ...

Why ADCs Are Becoming Oncology’s Most Reliable Trend

MARKET TRENDS

10 Feb 2025

Why ADCs Are Becoming Oncology’s Most Reliable Trend

Landmark ADC deals from 2023–2024 and new 2025 approvals underscore sustained momentum in targeted cancer care

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.